ethyl 6-(4-((2-(1H-indazol-4-yl)-4-morpholinothieno[3,2-c]pyrimidin-6-yl)methyl)piperazin-1-yl)hexanoate | 1235450-18-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并嘧啶酮衍生物
• 英文名称: ethyl 6-(4-((2-(1H-indazol-4-yl)-4-morpholinothieno[3,2-c]pyrimidin-6-yl)methyl)piperazin-1-yl)hexanoate
• 英文别名: ethyl 6-(4-((2-(1H-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)hexanoate；ethyl 6-[4-[[2-(1H-indazol-4-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]piperazin-1-yl]hexanoate
• CAS: 1235450-18-6
• 化学式: C₃₀H₃₉N₇O₃S
• 分子量: 577.751
• InChiKey: JPEDQRIYRDULPN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  41
• 可旋转键数：
  12
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  128
• 氢给体数：
  1
• 氢受体数：
  10

文献信息

• PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY
  申请人：Cai Xiong

  公开号：US20100222343A1

  公开（公告）日：2010-09-02

  The instant application relates to deazapurines, thienopyrimidines and furopyrimidines with zinc-binding moiety based derivatives and their use in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.

  本实用新型涉及具有基于锌结合基团的脱氮嘌呤、噻吩嘧啶和呋喃嘧啶衍生物及其在治疗与磷脂酰肌醇3-激酶相关的疾病和疾病方面的应用，例如癌症。本实用新型进一步涉及与组蛋白去乙酰化酶相关的疾病和同时涉及组蛋白去乙酰化酶和磷脂酰肌醇3-激酶相关的疾病的治疗。
• Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
  申请人：Curis, Inc.

  公开号：US10336770B2

  公开（公告）日：2019-07-02

  The instant application relates to deazapurines, thienopyrimidines and furopyrimidines with zinc-binding moiety based derivatives and their use in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.

  本申请涉及去氮嘌呤类、噻吩嘧啶类和呋喃嘧啶类与锌结合基的衍生物，以及它们在治疗磷酸肌酸 3- 激酶相关疾病和紊乱（如癌症）中的用途。本申请还涉及组蛋白去乙酰化酶相关疾病以及组蛋白去乙酰化酶和磷酸肌酸 3-激酶相关疾病的治疗。
• US8367663B2
  申请人：——

  公开号：US8367663B2

  公开（公告）日：2013-02-05
• US8461157B2
  申请人：——

  公开号：US8461157B2

  公开（公告）日：2013-06-11